Amarin Corp Plc (AMRN)

[Number sleven]

Rose, If we step back and look at where we are at, our position isn't so bad. We only have one real problem. (Generic approval for the US market.) That is no small problem. Generic competition so far has done no real damage to our business. Teva was my biggest concern and they don't even appear to be looking for a supply. Looks like our little molecule might represent the best therapy for the pandemic. Beyond the courts I would think management is exploring other options to fix our problem.
Who knows. It's possible we are all to pessimistic.
Sleven,